Mechanism of met oncogene activation - PubMed (original) (raw)
Mechanism of met oncogene activation
M Park et al. Cell. 1986.
Abstract
The met oncogene activated in vitro by treatment of a human osteogenic sarcoma (HOS) cell line with N-methyl-N'-nitronitrosoguanidine (MNNG) is related to the tyrosine kinase gene family. Probes from the met oncogene locus recognize two distinct transcripts of 9.0 kb and 10.0 kb which are independently expressed in a cell-type-specific fashion. While the met proto-oncogene locus expresses the 9.0 kb RNA and maps to human chromosome 7q21-31, the locus expressing the 10.0 kb RNA, (tpr; translocated promoter region) maps to human chromosome 1. Both MNNG-HOS cells and met NIH 3T3 transformants express a novel 5.0 kb RNA which represents a hybrid transcript with 5' sequences derived from tpr and 3' sequences from the met proto-oncogene. Treating HOS cells in vitro with MNNG, a known clastogenic carcinogen, resulted in fusion of two chromosomally disparate loci, met and tpr, generating the active met oncogene.
Similar articles
- The human met oncogene is a member of the tyrosine kinase family.
Gonzatti-Haces M, Park M, Dean M, Blair DG, Vande Woude GF. Gonzatti-Haces M, et al. Princess Takamatsu Symp. 1986;17:221-32. Princess Takamatsu Symp. 1986. PMID: 3332011 Review. - Activation of the met oncogene in the human MNNG-HOS cell line involves a chromosomal rearrangement.
Tempest PR, Reeves BR, Spurr NK, Rance AJ, Chan AM, Brookes P. Tempest PR, et al. Carcinogenesis. 1986 Dec;7(12):2051-7. doi: 10.1093/carcin/7.12.2051. Carcinogenesis. 1986. PMID: 3779899 - Analysis by pulsed field gel electrophoresis reveals complex rearrangements in two MET alleles in a chemically-treated human cell line, MNNG-HOS.
Testa JR, Park M, Blair DG, Kalbakji A, Arden K, Vande Woude GF. Testa JR, et al. Oncogene. 1990 Oct;5(10):1565-71. Oncogene. 1990. PMID: 2250912 - The trk family of oncogenes and neurotrophin receptors.
Lamballe F, Klein R, Barbacid M. Lamballe F, et al. Princess Takamatsu Symp. 1991;22:153-70. Princess Takamatsu Symp. 1991. PMID: 1844238 Review.
Cited by
- Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.
Estevam GO, Linossi EM, Macdonald CB, Espinoza CA, Michaud JM, Coyote-Maestas W, Collisson EA, Jura N, Fraser JS. Estevam GO, et al. Elife. 2024 Sep 13;12:RP91619. doi: 10.7554/eLife.91619. Elife. 2024. PMID: 39268701 Free PMC article. - Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning.
Estevam GO, Linossi EM, Rao J, Macdonald CB, Ravikumar A, Chrispens KM, Capra JA, Coyote-Maestas W, Pimentel H, Collisson EA, Jura N, Fraser JS. Estevam GO, et al. bioRxiv [Preprint]. 2024 Jul 18:2024.07.16.603579. doi: 10.1101/2024.07.16.603579. bioRxiv. 2024. PMID: 39071407 Free PMC article. Preprint. - The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy.
Crepaldi T, Gallo S, Comoglio PM. Crepaldi T, et al. Pharmaceuticals (Basel). 2024 Mar 30;17(4):448. doi: 10.3390/ph17040448. Pharmaceuticals (Basel). 2024. PMID: 38675409 Free PMC article. - Single nucleotide variants in nuclear pore complex disassembly pathway associated with poor survival in osteosarcoma.
Jacobs JE, Davis L, McWeeney S. Jacobs JE, et al. Front Genet. 2024 Mar 18;15:1303404. doi: 10.3389/fgene.2024.1303404. eCollection 2024. Front Genet. 2024. PMID: 38562379 Free PMC article. - Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions.
Al-Ghabkari A, Huang B, Park M. Al-Ghabkari A, et al. Cells. 2024 Jan 25;13(3):218. doi: 10.3390/cells13030218. Cells. 2024. PMID: 38334610 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous